For the above reasons, anti-VEGF therapy performed under topical anesthesia was preferred for treatment with ROP during our clinical practice, and laser therapy was the used option for ROP with the risk of obvious fibrosis or the recurrent eyes. The gene discussed is VEGFA; the disease is retinopathy of prematurity.